阴性筛查对比增强乳腺摄影后的间期癌发生率与特征
该回顾性单中心研究纳入2015年1月至2021年12月连续筛查性对比增强乳腺摄影(CEM),在6120次阴性筛查中诊断14例间期癌,总体间期癌率为2.29/1000次检查,占全部诊断癌症的13%。
要点
- 阴性CEM后1年内间期癌率为2.29/1000次检查,占全部癌症13%。
- 71%间期癌在先前CEM上为隐匿性,阅片时需警惕背景实质强化干扰。
- 浸润性间期癌更常伴中度或显著背景实质强化(75% vs 30%)。
核心结论
- CEM筛查后间期癌率为2.29/1000次检查,占全部诊断癌症的13%。
- 多数间期癌在先前阴性CEM上为隐匿性(10/14,71%)。
研究设计与样本
- 回顾性单中心研究,纳入2015年1月至2021年12月连续筛查性CEM检查。
- 共6911次筛查CEM,来自2756例女性,中位年龄53岁(IQR 47-60岁)。
- 由两名乳腺放射科医师独立复核先前阴性CEM,将间期癌分类为漏诊、误判或隐匿。
- 连续变量采用Wilcoxon秩和检验,分类变量采用Fisher精确检验或χ2检验比较间期癌与筛查检出癌的特征。
关键影像表现/征象
- 浸润性间期癌在先前CEM上更常表现为中度或显著背景实质强化(6/8,75%),而筛查检出癌为17/57(30%)。
- 多数间期癌(10/14,71%)在先前筛查CEM上为隐匿性,即影像上未见明确异常。
诊断标准与关键数值
- 总体间期癌率定义为阴性筛查CEM后1年内诊断的癌症数除以阴性筛查检查数,结果为2.29/1000次检查。
- 症状性间期癌率为0.82/1000次检查(5/6120)。
- 间期癌占全部诊断癌症(间期癌+筛查检出癌)的13%(14/106)。
临床应用与阅片要点
- 阅片时需注意中度或显著背景实质强化可能掩盖浸润性癌,增加间期癌风险。
- 对背景实质强化明显的阴性CEM,报告时可提示临床结合其他影像或密切随访。
- 间期癌多数在先前CEM上隐匿,提示需关注快速生长或MRI隐匿性病变的可能。
局限性
- 回顾性单中心设计,结论外推需谨慎。
- 间期癌事件数较少(14例),统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To determine the interval cancer rate (ICR) after negative screening contrast-enhanced mammography (CEM) and compare the characteristics of interval cancers (ICs) with those of CEM screen-detected cancers. Materials and Methods This retrospective, single-institution study included consecutive screening CEM examinations performed from January 2015 through December 2021. ICs diagnosed within 1 year of a negative screening CEM and all CEM screen-detected cancers were identified. Two breast radiologists independently reviewed prior negative CEM examinations to classify ICs as missed, misinterpreted, or occult. Patient- and lesion-level characteristics were compared between ICs and screen-detected cancers using the Wilcoxon rank sum test for continuous variables and the Fisher exact or χ2 tests for categorical variables. Results The study included 6911 screening CEM examinations in 2756 female patients (median age, 53 years; IQR, 47-60 years). Among 6120 negative screening examinations, 14 ICs were diagnosed in 14 patients. The overall ICR was 2.29 cancers per 1000 examinations, and the symptomatic ICR was 0.82 per 1000 examinations (five of 6120). ICs accounted for 13% (14 of 106) of all cancers diagnosed (interval and screen detected). Invasive ICs occurred more frequently in the setting of moderate or marked background parenchymal enhancement than screen-detected cancers (six of eight, 75% vs 17 of 57, 30%; P = .02). Most ICs (10 of 14, 71%) were occult on prior screening CEM. Conclusion The ICR after CEM was 2.29 cancers per 1000 examinations, representing 13% of all cancers diagnosed. Most ICs were occult at prior CEM, and invasive ICs were more frequently associated with moderate or marked background parenchymal enhancement when compared with CEM screen-detected cancers. Keywords: Mammography, Breast, Interval Cancers Supplemental material is available for this article. © RSNA, 2026.
引用
- Amir T, Lee CH, Eskreis-Winkler S, et al. Interval Cancers after Negative Screening Contrast-enhanced Mammography. Radiol Imaging Cancer. 2026. PMID: 42065648. doi:10.1148/rycan.250559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。